SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
Epistemonikos ID: 04e7f95d80da2642d4cbfbfbd7db6951a3b1fa31
First added on: May 15, 2024